Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesSignificant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
Clinical Endocrinology, 07/13/09
Colao A et al. - ATG 120 mg in newly diagnosed patients with acromegaly controls GH and IGF-I secretion in 53·8% and induces > 25% tumour shrinkage in 76·9% during a 12-month period. The treatment was associated with improvement of clinical symptoms and with a good safety profile.
Related Articles
The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 88%
Associations between Body Composition, Circulating Interleukin-1 Receptor Antagonist, Osteocalcin, and Insulin Metabolism in Active Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/20/09
Relevance Score: 87%
The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09
Relevance Score: 87%
Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09
Relevance Score: 87%
Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09
Relevance Score: 85%
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Role of the Perifornical Hypothalamic Monoamine Neurotransmitter Systems in Anorectic Effects of Endotoxin
Neuroendocrinology, 12/01/09
Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies
Oncology (Karger), 11/25/09
ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropancreatic Neuroendocrine Tumor Cell Lines
Neuroendocrinology, 11/24/09
Sponsor
Article Search
Sponsor